Bowman & Co S.C. Sells 1,158 Shares of DexCom, Inc. (NASDAQ:DXCM)

Bowman & Co S.C. lowered its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 17.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 5,519 shares of the medical device company’s stock after selling 1,158 shares during the period. Bowman & Co S.C.’s holdings in DexCom were worth $429,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in DXCM. Sax Wealth Advisors LLC lifted its holdings in shares of DexCom by 135.8% in the fourth quarter. Sax Wealth Advisors LLC now owns 14,284 shares of the medical device company’s stock worth $1,111,000 after buying an additional 8,226 shares in the last quarter. Merit Financial Group LLC purchased a new position in shares of DexCom during the 4th quarter valued at about $228,000. Avanza Fonder AB bought a new stake in shares of DexCom in the 4th quarter worth approximately $3,731,000. Yarbrough Capital LLC purchased a new stake in DexCom during the fourth quarter valued at about $217,000. Finally, Carnegie Investment Counsel grew its position in DexCom by 11.0% during the 4th quarter. Carnegie Investment Counsel now owns 3,530 shares of the medical device company’s stock worth $275,000 after acquiring an additional 350 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors.

DexCom Stock Performance

Shares of DexCom stock opened at $84.38 on Friday. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. DexCom, Inc. has a 52 week low of $62.34 and a 52 week high of $142.00. The firm’s 50 day moving average is $78.17 and its two-hundred day moving average is $77.98. The firm has a market capitalization of $32.96 billion, a P/E ratio of 50.53, a P/E/G ratio of 2.00 and a beta of 1.12.

Insider Transactions at DexCom

In other news, EVP Sadie Stern sold 4,259 shares of the company’s stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the transaction, the executive vice president now directly owns 71,192 shares of the company’s stock, valued at $5,320,178.16. This represents a 5.64 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 0.30% of the company’s stock.

Analyst Ratings Changes

Several analysts recently issued reports on DXCM shares. Canaccord Genuity Group raised their target price on DexCom from $89.00 to $99.00 and gave the stock a “buy” rating in a research note on Monday, December 9th. StockNews.com cut shares of DexCom from a “buy” rating to a “hold” rating in a report on Saturday, November 2nd. Sanford C. Bernstein upped their price target on shares of DexCom from $82.00 to $86.00 and gave the stock an “outperform” rating in a research note on Friday, October 25th. JPMorgan Chase & Co. lifted their target price on shares of DexCom from $75.00 to $85.00 and gave the stock a “neutral” rating in a research report on Friday, October 25th. Finally, Baird R W upgraded DexCom from a “hold” rating to a “strong-buy” rating in a research note on Thursday. Five equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $99.29.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.